MOTS-C
Mitochondrial Open Reading Frame of the 12S rRNA-c
MOTS-C is a 16-amino acid mitochondrial-derived peptide (MDP) encoded by mitochondrial DNA. It plays a crucial role in regulating metabolic homeostasis, glucose metabolism, and insulin sensitivity. MOTS-C has shown promising therapeutic potential in aging, diabetes management, cardiovascular health, and physical performance enhancement. Currently in research phase with no clinical approval.
MOTS-C Dosing Guide
Primary Benefits
- Enhanced mitochondrial function and biogenesis
- Improved glucose metabolism and insulin sensitivity
- Age-related physical performance improvement
- Cardiovascular protection and heart health
- Metabolic stress resistance and homeostasis
How It Works
MOTS-C functions as a mitochondrial-nuclear communication peptide that activates AMP-activated protein kinase (AMPK) signaling pathways. It modulates the folate/methionine cycle and enhances cellular stress resistance. MOTS-C interacts with nuclear genes to regulate metabolic homeostasis, particularly glucose metabolism and insulin sensitivity. The peptide promotes mitochondrial biogenesis, improves oxidative metabolism, and provides cytoprotection against age-related cellular damage.
Quick Reference
Typical Dosage Range
Research protocols vary significantly: Standard 20-day cycles use 5 mg subcutaneously every 5 days (total 20 mg per cycle), repeated 4 times yearly. Extended 30-day protocols use 10 mg weekly for 4 weeks (40 mg total), repeated within 6 months. Maximum protocols involve 5 mg three times weekly for 4-6 weeks (60-90 mg total) or 10 mg weekly for 10 weeks (100 mg total). Animal studies used 0.5-15 mg/kg/day intraperitoneally or subcutaneously.
Administration Methods
MOTS-C is typically administered via subcutaneous injection using insulin-type syringes. Injection sites include abdomen, thigh, or upper arm with site rotation to prevent tissue damage. Research protocols suggest injection timing is flexible (morning or evening), independent of meals. Reconstitution requires bacteriostatic water, with prepared solutions stable for 14-21 days when refrigerated. Proper sterile technique is essential to prevent infection.
Medical Disclaimer
MOTS-C is an experimental peptide not approved by the FDA for therapeutic use. It is banned by WADA for athletic competition. All information is for educational purposes only and should not constitute medical advice. Consult healthcare professionals before considering any peptide therapy. Long-term safety and efficacy in humans remain unknown.